LncRNA FAM83H-AS1在子宫内膜癌中作为致癌因子及其作用网络  

The role of LncRNA FAM83H-AS1 as an oncogenic factor in endometrial carcinoma and its associated signaling network

作　　者：宋晓霞 姜秋慧 周晓丽[1] 刘晓妍 王倩倩[1] 赵晓丽 SONG Xiao-xia;JIANG Qiu-hui;ZHOU Xiao-li;LIU Xiao-yan;WANG Qian-qian;ZHAO Xiao-li(Department of Gynecology,the Fifth Clinical Medical College of Henan University of Chinese Medicine(Zhengzhou People′s Hospital),Zhengzhou 450053,Henan,China)

机构地区：[1]河南中医药大学第五临床医学院(郑州人民医院)妇科,河南郑州450053

出　　处：《广东医学》2024年第5期534-539,共6页Guangdong Medical Journal

基　　金：河南省二〇二二年科技发展计划(222102310488);河南省医学科技攻关联合共建项目(LHGJ20220794)。

摘　　要：目的探讨LncRNA FAM83H-AS1在子宫内膜癌(Endometrial carcinoma,EC)中的表达及其作用网络分析。方法收集82例EC患者的癌组织与癌旁组织,检测组织中FAM83H-AS1表达水平。ROC曲线分析FAM83H-AS1在EC中的诊断价值,此外分析FAM83H-AS1与EC患者临床病理资料的关系。LncRNA SNP网站构建LncRNA-miRNA作用网络。GEPIA网站预测FAM83H-AS1的共表达基因并借助KEGG富集分析确定FAM83H-AS1共表达基因富集的通路。预测FAM83H-AS1和患者预后和免疫的关系。干预EC细胞中FAM83H-AS1的表达,细胞计数试剂盒-8(cell counting kit 8,CCK8)法检测细胞增殖活力,Transwell检测细胞侵袭。结果与癌旁组织比较,癌组织中FAM83H-AS1表达增强(P<0.05),且FAM83H-AS1能够作为EC诊断的一个有效分子(AUC=0.841,P<0.01)。FAM83H-AS1表达与EC患者的临床分期、肌层浸润程度有关(均P<0.05)。多个miRNA和mRNA和FAM83H-AS1存在关联,FAM83H-AS1的共表达基因主要富集在细胞周期、内吞作用以及RNA降解等通路中。UALCAN网站预测发现FAM83H-AS1高表达患者预后更差,Timer网站预测发现FAM83H-AS1表达与CD8+T细胞和巨噬细胞相关。与Blank组比较,过表达FAM83H-AS1促进EC细胞的增殖活力和侵袭而敲减FAM83H-AS1则抑制EC细胞的增殖活力和侵袭(均P<0.05)。结论FAM83H-AS1可能是EC的致癌驱动因子,可作为治疗EC的潜在靶点。Objective To investigate the expression and signaling network of LncRNA FAM83H-AS1 in endometrial carcinoma(EC).Methods Cancer tissues and adjacent tissues from 82 patients with esophageal cancer(EC)were collected for detection of the expression levels of FAM83H-AS1.The diagnostic value of FAM83H-AS1 in EC was analyzed by ROC curve,and the correlation between FAM83H-AS1 and clinical pathological data of EC patients was also analyzed.Long non-coding RNA(LncRNA)SNP sites were used to construct an LncRNA-miRNA interaction network.The GEPIA website was used to predict the co-expressed genes of FAM83H-AS1,and KEGG enrichment analysis was conducted to determine the pathways enriched in co-expressed genes of FAM83H-AS1.The correlations between FAM83H-AS1,patient prognosis,and immunity was predicted.The expression of FAM83H-AS1 in EC cells was intervened,and cell proliferation activity was detected using the Cell Counting Kit-8(CCK-8)method,while cell invasion was assessed using Transwell.Results Compared with adjacent tissues,FAM83H-AS1 expression was enhanced in cancer tissues(P<0.05),and FAM83H-AS1 could serve as an effective molecular marker for EC diagnosis(AUC=0.841,P<0.01).The expression of FAM83H-AS1 was related to the clinical staging and depth of muscle invasion in EC patients(both P<0.05).Multiple miRNAs and mRNAs were found to be associated with FAM83H-AS1,and the co-expressed genes of FAM83H-AS1 were mainly enriched in pathways such as the cell cycle,endocytosis,and RNA degradation.UALCAN website predicted that patients with high expression of FAM83H-AS1 had a poorer prognosis,and Timer website predicted that the expression of FAM83H-AS1 was associated with CD8+T cells and macrophages.Compared with the Blank group,overexpression of FAM83H-AS1 promoted the proliferation and invasion of EC cells,while knockdown of FAM83H-AS1 inhibited the proliferation and invasion of EC cells(all P<0.05).Conclusion FAM83H-AS1 may be a carcinogenic driver in EC and could serve as a potential therapeutic target for treating EC.

关 键 词：LncRNA FAM83H-AS1 免疫细胞 致癌因子 生物信息学分析 

分 类 号：R737.33[医药卫生—肿瘤] R392[医药卫生—临床医学]